Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
M e Terra and Unilever (A)
Paine, Lynn Sharp; Costas, Ruth; Zogbi, PriscillaCaso HBS-320075-EConocimiento y comunicaciónThe case concerns the sale of Mae Terra, one of Brazil's leading brands for packaged organic foods, to the consumer goods giant Unilever in 2017. Working with Unilever management, Mae Terra's CEO Alexandre Borges must determine whether and how to keep Mae Terra's B Certification, which attests to its commitment to having a positive social and environmental impact, and what internal governance mechanisms will enable MaeTerra to maintain its missio...Desde 8,20 €
-
M e Terra and Unilever (B) (Portuguese version)
Paine, Lynn Sharp; Costas, Ruth; Cal, MarianaCaso HBS-322P01Conocimiento y comunicaciónUnilever is making strides to integrate the operations of Mae Terra-one of Brazil's leading brands for packaged organic foods-into its own structures, after acquiring the company in 2017. Mae Terra's CEO, Alexandre Borges, must decide whether to implement his original plan as written into the purchase and sales agreement to create an advisory board to help ensure that the company maintain its mission, values and practices as part of a volume-driv...Desde 5,74 €
-
M e Terra and Unilever (A) (Portuguese version)
Paine, Lynn Sharp; Costas, Ruth; Zogbi, PriscillaCaso HBS-321P03Conocimiento y comunicaciónThe case concerns the sale of Mae Terra, one of Brazil's leading brands for packaged organic foods, to the consumer goods giant Unilever in 2017. Working with Unilever management, Mae Terra's CEO Alexandre Borges must determine whether and how to keep Mae Terra's B Certification, which attests to its commitment to having a positive social and environmental impact, and what internal governance mechanisms will enable MaeTerra to maintain its missio...Desde 8,20 €
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1716-EFinanzasIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Desde 8,20 €
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1715-EFinanzasThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Desde 8,20 €
-
Genzyme and Relational Investors: Science and Business Collide? - Teaching Note
Eades, Kenneth M.; Matos, PedroNota del Instructor DARDEN-F-1660TN-EFinanzasTeaching note for product F-1660Desde 0,00 €
-
Guth v. Loft: Synopsis (Spanish Version)
Paine, Lynn Sharp; Bruner, Christopher M.Caso HBS-313S09Conocimiento y comunicaciónProporciona una visión general breve de la Corte Suprema de la opinión de Delaware en el caso de Guth 1939 v. Loft, una aplicación ampliamente citado de la "doctrina oportunidad corporativa." Explora los principios de derecho corporativo que regulan cuando un gerente corporativo puede o no puede tomar ventaja de una oportunidad de negocio relacionada con el negocio de la corporación, a la luz de las obligaciones fiduciarias del gestor.Desde 8,20 €
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCaso DARDEN-F-1660-EFinanzasThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Desde 8,20 €